Founded in Chicago, Illinois, Saros Therapeutics focuses on enhancing patients' responses to immunotherapy. The company’s core mission is to develop and commercialize novel immunotherapies that improve and extend the lives of cancer patients. Saros Therapeutics has engineered a nanoparticle technology that safely targets and enhances pathways of innate immune activation, beginning with the STING pathway. This innovative approach aims to overcome the limitations of previous agonists by effectively targeting tumor tissue, macrophages, and dendritic cells.

Saros Therapeutics has attracted notable investors and affiliations within the biotech and medical communities, although specific names are not disclosed. The company has made significant strides in the field of cancer immunotherapy, with its nanoparticle technology representing a breakthrough in targeting and activating the immune system. The impact of Saros Therapeutics is seen in its potential to revolutionize cancer treatment by making immunotherapies more effective and accessible to patients, thereby improving patient outcomes and quality of life.